STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Want to see DE:SBS full AI Analyst Report?
SBS Stock Chart & Stats
€22.40
€0.10(0.34%)
At close: 4:00 PM EST
€22.40
€0.10(0.34%)
Day’s Range― - ―
52-Week Range€16.34 - €33.10
Previous CloseN/A
Volume977.00
Average Volume (3M)15.55K
Market Cap
€215.16M
Enterprise Value€324.24M
Total Cash (Recent Filing)€23.06M
Total Debt (Recent Filing)€132.13M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.00Price Target Upside29.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.49
Revenue Forecast (FY)€269.27M
Bulls Say, Bears Say
Bulls Say
OEM/ODM Recurring Manufacturing ModelA core OEM/ODM model with multi-year partner contracts drives recurring series production revenue and development fees. This creates durable cash flow potential tied to partners' installed bases and new platform ramps, improving revenue visibility versus transactional businesses.
Reasonable Balance-sheet CushionEquity materially exceeds net debt, giving the company moderate leverage and financial headroom to absorb near-term operating volatility. Stable total assets and equity provide capacity to fund development programs and support partner commitments without immediate solvency pressure.
€125m Syndicated Loan Enhances LiquiditySecuring a €125m syndicated facility materially improves financing flexibility, reduces short-term refinancing risk and supports investment in development programs or production ramps. This structural liquidity tool helps manage periods of negative FCF and execute multi-year OEM projects.
Bears Say
Multi-year Revenue DeclineSustained revenue contraction over multiple years erodes operating leverage and signals structural demand or execution issues. Persistent top-line declines make it harder to cover fixed costs, impair margin recovery and limit ability to invest in new platform development without partners.
Margin Compression And Profit DeteriorationFalling gross and EBIT margins reduce internal funding for R&D and capex and indicate unfavorable product mix and pricing pressure. A shift to net loss in 2025 shows operating leverage has failed to absorb lower revenue, threatening long-term profitability restoration if trends persist.
Volatile And Recently Negative Cash GenerationSharp swings in operating and free cash flow create funding uncertainty and increase reliance on external financing. Negative FCF in 2025 limits capacity for organic investment, raises refinancing risk between loan rollovers, and weakens ability to support partner programs during downturns.
STRATEC Biomedical News
SBS FAQ
What was STRATEC Biomedical AG’s price range in the past 12 months?
STRATEC Biomedical AG lowest stock price was €16.34 and its highest was €33.10 in the past 12 months.
What is STRATEC Biomedical AG’s market cap?
STRATEC Biomedical AG’s market cap is €215.16M.
When is STRATEC Biomedical AG’s upcoming earnings report date?
STRATEC Biomedical AG’s upcoming earnings report date is May 11, 2026 which is in 2 days.
How were STRATEC Biomedical AG’s earnings last quarter?
Currently, no data Available
Is STRATEC Biomedical AG overvalued?
According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued.
Does STRATEC Biomedical AG pay dividends?
STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.71%. See more information on STRATEC Biomedical AG dividends here
What is STRATEC Biomedical AG’s EPS estimate?
STRATEC Biomedical AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does STRATEC Biomedical AG have?
STRATEC Biomedical AG has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of STRATEC Biomedical AG?
Currently, no hedge funds are holding shares in DE:SBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
STRATEC Biomedical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.21%
12-Months-Change
Fundamentals
Return on Equity
-0.10%
Trailing 12-Months
Asset Growth
-3.81%
Trailing 12-Months
Company Description
STRATEC Biomedical AG
STRATEC Biomedical (SBS) is a leading provider of automation and instrumentation solutions for the medical technology and diagnostics industries. The company specializes in the development and production of complex systems used in laboratories and point-of-care settings, offering products that facilitate sample preparation, analysis, and result generation. STRATEC's core offerings include fully automated systems, software solutions, and consumables that support a wide range of applications, including immunoassays, molecular diagnostics, and clinical chemistry.
SBS Stock 12 Month Forecast
Average Price Target
€29.00
▲(29.46% Upside)
Technical Analysis
Draegerwerk AG & Co. KGaA
―
Eckert & Ziegler Strahlen und Medizintechnik
―
First Sensor
―
Gerresheimer
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---